Bio News

Israel-based Teva and Samsung Bioepis have signed an agreement to jointly develop and commercialize up to six biosimilar candidates.
Samsung Bioepis will handle development, regulatory activities and manufacturing, while Teva will be responsible for sales in the United States, Europe, Canada and other markets.
The companies also agreed on an option to expand the partnership to other regions.

Biobook Team
biobookmedia@biobook.co.krCosentyx Approved by FDA for 11th Indication: Polymyalgia Rheumatica
Delonix and Singapore’s A*STAR IDL to Collaborate on Vaccine Against Drug-Resistant Klebsiella pneumoniae
Brazilian Health Regulatory Agency Approves Oral Plaque Psoriasis Treatment Icotyde
Medtronic to Acquire Contego Medical for $380 Million
Brazilian Health Regulatory Agency Approves Botox for Masseter Muscle Prominence
Roche’s oral SERD Itovebi wins FDA approval, cutting risk of progression by 62%